Unknown

Dataset Information

0

Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.


ABSTRACT: To determine the effect of adding cilostazol (100 mg b.i.d.) to standard-dose clopidogrel (75 mg/d) (TRIPLE) compared with double-dose clopidogrel (150 mg/d) (DOUBLE) and the influence of the cytochrome P450 (CYP2C19*2/*3, CYP3A5*3)and ATP-binding cassette subfamily B1(ABCB1 C3435T) genetic polymorphisms in type 2 diabetes (T2DM) patients.T2DM patients were treated with TRIPLE (n = 41) or DOUBLE (n = 39) after percutaneous coronary intervention. Conventional aggregometry and VerifyNow were performed at baseline and at 30 days. The primary end point was absolute change in 20-?M ADP-induced maximal platelet aggregation (?MPA(20)) between baseline and switching values.TRIPLE versus DOUBLE showed greater ?MPA(20) (22.9 ± 11.6 vs.12.7 ± 15.5%; difference, 10.2% [95% CI 4.2-16.3]; P < 0.001). Carriage of one (? coefficient, -5.4%; P = 0.162) and two CYP2C19 loss-of-function allele(s) (-8.3%; P = 0.007) were associated with lower ?MPA(20) in DOUBLE-treated patients, but not in TRIPLE-treated patients.Among T2DM patients, adding cilostazol achieves greater platelet inhibition compared with clopidogrel (150 mg/d), which is not influenced by genetic polymorphisms.

SUBMITTER: Jeong YH 

PROVIDER: S-EPMC3476883 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.

Jeong Young-Hoon YH   Tantry Udaya S US   Park Yongwhi Y   Kwon Tae Jung TJ   Park Jeong Rang JR   Hwang Seok-Jae SJ   Bliden Kevin P KP   Koh Eun-Ha EH   Kwak Choong Hwan CH   Hwang Jin-Yong JY   Kim Sunjoo S   Gurbel Paul A PA  

Diabetes care 20120726 11


<h4>Objective</h4>To determine the effect of adding cilostazol (100 mg b.i.d.) to standard-dose clopidogrel (75 mg/d) (TRIPLE) compared with double-dose clopidogrel (150 mg/d) (DOUBLE) and the influence of the cytochrome P450 (CYP2C19*2/*3, CYP3A5*3)and ATP-binding cassette subfamily B1(ABCB1 C3435T) genetic polymorphisms in type 2 diabetes (T2DM) patients.<h4>Research design and methods</h4>T2DM patients were treated with TRIPLE (n = 41) or DOUBLE (n = 39) after percutaneous coronary interventi  ...[more]

Similar Datasets

| S-EPMC5721756 | biostudies-literature
| S-EPMC3806846 | biostudies-literature
| S-EPMC5533039 | biostudies-literature
| S-EPMC6990835 | biostudies-literature
| S-EPMC3521288 | biostudies-literature
| S-EPMC4552627 | biostudies-literature
| S-EPMC7592033 | biostudies-literature
| S-EPMC4833149 | biostudies-literature
| S-EPMC7118520 | biostudies-literature
| S-EPMC4248610 | biostudies-literature